AIM-quoted refugee from the Full List, Amberley Group, the former speciality mineral and chemical outfit now a shell company run by French entrepreneur Guy Naggar, lost £68,000 in the six months to October and is continuing to 'search for opportunities to create significant shareholder value in the long term'. Robert Tyerman reports.
Amberley, which raised £1 million at 10p plus warrants in August, says its net asset value at the end of October was £2.45 million, or 6.95p a share, including £2.3 million cash. In late October, the company bought contracts for difference over ten million shares in fully listed fibres, umbrellas and wall coverings group Chapelthorpe at an average price of 18.9p a share, against today's 20p.
Naggar says Amberley has looked at 'a number of potential investments, in both the public and private arena' and promises that 'shareholders will be kept informed of any major developments'. Positive news would be welcome indeed for investors who have seen the shares halve to 12p since 2000.
The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info
Latest small-cap and growth company news
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
One View listed on AIM via a reverse takeover back in March. It has developed software that provides retailers with a combined view of their customers history in both online and in-store shopping channels. This sort of digital engagement is a big opportunity for retailers to boost their sales.
Angle is making good progress with its ‘Parsortix’ system which uses a precision-etched cassette to ‘sieve’ patient blood samples and capture cancerous tumour cells. The first major trial is now underway in ovarian cancer, led by the University of Vienna.
Transportation software specialist Tracsis has won a significant contract in the US. This looks like it could be a breakthrough which opens up the vast North American railroad market to this Leeds based company.
ScS Group confirms it hasn't seen a slowdown in demand post-Brexit. Momentum has continued since the update in early June, with like-for-like sales order intake of 14.8 per cent for the first financial year ending in July.